Ultrasound enhanced central venous catheter

Information

  • Patent Grant
  • 7993308
  • Patent Number
    7,993,308
  • Date Filed
    Friday, January 28, 2005
    20 years ago
  • Date Issued
    Tuesday, August 9, 2011
    13 years ago
Abstract
A central venous catheter comprises an ultrasound assembly. In one arrangement, the radiating member is used to remove a blockage from the central venous catheter. In another arrangement, inserting an ultrasound assembly into a central venous catheter. The ultrasound assembly comprises an ultrasound radiating member mounted on an elongate support structure. The method further comprises positioning the ultrasound assembly within the central venous catheter such that the ultrasound radiating member is adjacent to a deposited material formed on a portion of the central venous catheter. The method further comprises supplying an electrical current to the ultrasound radiating member to expose the deposited material to ultrasonic energy. The method further comprises passing a therapeutic compound through the central venous catheter to expose the deposited material to the therapeutic compound simultaneously with ultrasonic energy.
Description
FIELD OF THE INVENTION

The present invention relates generally to use of an ultrasound assembly with a central venous catheter, and more specifically to using ultrasonic energy to enhance the efficacy of a central venous catheter.


BACKGROUND OF THE INVENTION

The term “central venous catheter” or “CVC,” refers generally, in addition to its ordinary meaning, to a catheter that has been inserted into a vein of the vascular system. Although CVCs have many varied applications, CVCs are frequently used when a patent requires frequent or continuous injections of medications or fluids for nutritional support. Common CVC applications include, but are not limited to, chemotherapy, long-term intravenous antibiotics, long-term pain medications, long-term intravenous nutrition, frequent blood draws, dialysis, and plasmapheresis. Therefore, a CVC can be used to deliver fluids to, or extract fluids from, the cardiovascular system.


In a wide variety of medical applications, the tip of a CVC is advanced into the superior vena cava (“SVC”) from an upper extremity jugular vein or subclavian vein. Other approaches and deployment locations can be used in other applications. CVCs are used in a wide variety of applications; one common application is in the provision of a therapeutic compound into a patient's vascular system.


When a CVC is used for an extended period, blockages can form within the CVC, or can form outside the CVC in the vein between the CVC and the blood vessel wall. For example, a blockage inside the CVC can be caused by drug precipitate or thrombus. Additionally, platelet aggregation or fibrin deposition can completely encase the surface of the CVC, or can form a sac around the distal end of the CVC. Conventionally, such blockages were removed, if at all, either by removing and replacing/cleaning the CVC or while the CVC is in place passing a clot-dissolving compound through the CVC to dissolve the blockage. However, removing the CVC catheter is generally not desirable and introducing a large quantity of clot-dissolving compounds into the vascular system can have negative side effects.


SUMMARY OF THE INVENTION

Therefore, a device capable of removing blockages or other materials from within or around a CVC, without removing the CVC and/or causing the negative side effects associated with the introduction of large quantities of clot-dissolving compounds into the vascular system, has been developed. In addition, an improved CVC that is capable of being outfitted with an ultrasound assembly is also provided.


Accordingly, one embodiment of the present invention comprises an elongate central venous catheter. The elongate central venous catheter having a distal region configured for insertion into a patient's vasculature. The elongate central venous catheter also has a fluid delivery lumen configured to allow a fluid to be delivered through the central venous catheter to the patient's vasculature. The apparatus further comprises an ultrasound assembly configured to be positioned adjacent to the central venous catheter distal region. The apparatus further comprises a temperature sensor configured to measure a temperature in a region adjacent to the ultrasound assembly.


According to one embodiment of the present invention, a method for removing a blockage from a central venous catheter comprises inserting an ultrasound assembly into a central venous catheter. The ultrasound assembly comprises an ultrasound radiating member mounted on an elongate support structure. The method further comprises positioning the ultrasound assembly within the central venous catheter such that the ultrasound radiating member is adjacent to a deposited material formed on a portion of the central venous catheter. The method further comprises supplying an electrical current to the ultrasound radiating member to expose the deposited material to ultrasonic energy. The method further comprises passing a blockage removal compound through the central venous catheter to expose the deposited material to the blockage removal compound simultaneously with ultrasonic energy.


According to another embodiment of the present invention, a method comprises exposing a deposited material formed on a central venous catheter to ultrasonic energy while the central venous catheter is positioned in a patient and exposing the deposited material to a blockage removal compound while the central venous catheter is positioned in a patient.


According to another embodiment of the present invention, a method for removing a deposited material from a catheter comprises supplying a blockage removal compound to the deposited material. The method further comprises exposing the deposited material to ultrasonic energy generated by an ultrasound radiating member positioned within the catheter. The method further comprises measuring a temperature on the catheter to provide an indication of progression of the removal of the deposited material from the catheter.





BRIEF DESCRIPTION OF THE INVENTION

Exemplary embodiments of the CVCs disclosed herein, and exemplary methods for using said CVCs are illustrated in the accompanying drawings, which are for illustrative purposes only. The drawings comprise the following figures, in which like numerals indicate like parts.



FIG. 1 is a perspective view of an exemplary embodiment of a distal end of a CVC structure having a fibrin sleeve formed thereover.



FIG. 2 is a perspective view of an exemplary embodiment of a distal end of a CVC structure having a intraluminal thrombus or clot formed therein.



FIG. 3 is a cross-sectional view of a CVC disposed within a patient's vasculature, wherein an ultrasound assembly is positioned within the CVC.



FIG. 4 is a side view of the ultrasound assembly positioned within the CVC of FIG. 3.



FIG. 5A is a cross-sectional view of a CVC having an embedded ultrasound radiating member.



FIG. 5B is a cross-sectional view of the CVC of FIG. 5A, taken along line 5B-5B.



FIG. 6 is a perspective illustration of a CVC elongate body having a suture wing in the catheter proximal region.





DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

As described above, material can be deposited in and around a CVC during extended use. Such deposition can adversely affect operation of the CVC, making it difficult or impossible to deliver therapeutic compounds or other materials through the CVC to the patient's vasculature. Therefore, improvements have been developed to mitigate the adverse affects associated with material deposition in or around a CVC. Exemplary embodiments of these improvements are disclosed herein.


A wide variety of CVC structures exist, and the improvements described herein are not intended to be limited to a particular CVC structure. Rather, the improvements are described in connection with a generic CVC structure, with the understanding that these improvements are not limited to use with that particular CVC structure. For example, CVCs can be configured with multiple lumens, rather than a single central lumen. For example, in one embodiment, a CVC catheter has been one lumen and five lumens. Multiple lumens can be used for introducing and withdrawing fluids and devices, such as a guidewire. Likewise, the improvements disclosed herein can be used with catheters other than CVC catheters, such as with catheters configured to be inserted into other regions of the vascular system.


Accordingly, the term “central venous catheter” refers generally, in addition to its ordinary meaning, to a catheter that has been inserted into a vein of the vascular system. In a wide variety of medical applications, the tip of a CVC is advanced into the superior vena cava (“SVC”) from an upper extremity jugular vein or subclavian vein. Other approaches and deployment locations can be used in other applications. CVCs are used in a wide variety of applications; one common application is in the provision of a therapeutic compound into a patient's vascular system.


As used herein, the term “therapeutic compound” refers broadly, without limitation, to a drug, medicament, dissolution compound, genetic material or any other substance capable of effecting physiological functions. Additionally, any mixture comprising any such substances is encompassed within this definition of “therapeutic compound”, as well as any substance falling within the ordinary meaning of these terms.


As used herein, the term “ultrasound energy” is a broad term and is used in its ordinary sense and means, without limitation, mechanical energy transferred through pressure or compression waves with a frequency greater than about 20 kHz. In one embodiment, the waves of the ultrasound energy have a frequency between about 500 kHz and 20 MHz and in another embodiment between about 1 MHz and 3 MHz. In yet another embodiment, the waves of the ultrasound energy have a frequency of about 3 MHz.


As used herein, the term “catheter” is a broad term and is used in its ordinary sense and means, without limitation, an elongate flexible tube configured to be inserted into the body of a patient, such as, for example, a body cavity, duct or vessel.


A distal region of a generic CVC structure is illustrated in FIGS. 1 and 2. As illustrated, a generic CVC comprises a flexible, elongate body 100 that forms a central lumen 110. The elongate body 100 has an outer surface 120, and is dimensioned to facilitate its passage through the peripheral vascular system. Generally, suitable materials and dimensions for the CVC can be selected readily based on the natural and anatomical dimensions of the particular treatment site and percutaneous access site. Examples of suitable CVC materials include, but are not limited to, extruded polytetrafluoroethylene (“PTFE”), polyethylenes (“PE”), polyamides and other similar materials. In CVCs configured for long term implantation, soft materials such as urethanes and silicones can be used to form the catheter body. Additionally, a CVC optionally includes a coating, such as a silver coating, to reduce the likelihood of infection.


In certain embodiments, the proximal region of the CVC is reinforced by braiding, mesh or other internal or external structures to provide increased kink resistance and pushability, thereby facilitating passage of the CVC through the patient's vasculature. In other embodiments, the CVC body can be reinforced by including a stylet in the CVC body, which serves to maintain rigidity of the CVC during passage through the patient's vasculature. In such embodiments, a thin, elongate wire can be used as a stylet.


In one embodiment, a CVC has an outer diameter between approximately 6 French and approximately 14 French.


A CVC optionally includes a suture wing or cuff in the catheter proximal region, which can be used to attach the proximal end of the CVC to the patient. For example, FIG. 6 illustrates a CVC elongate body 100 having a suture wing 190 in the catheter proximal region. The suture wing 190 can be constructed of a material suitable for attachment to a patient's body. In other embodiments, a cuff that may be made out of a material such as Dacron can be used. As illustrated, the CVC optionally includes a proximal hub 195 that can be used to supply fluid, such as a therapeutic compound, through a CVC lumen.


As described above, material often deposits in and around a CVC that has been positioned within a patent's vasculature for an extended period of time. Such blockages can be caused by therapeutic compound precipitate, platelet aggregation, or fibrin deposition. For example, FIG. 1 illustrates the formation of a fibrin sleeve 130 at the distal region of the CVC, and FIG. 2 illustrates the formation of a thrombus or clot 140 within the CVC central lumen 110. Either of these conditions can adversely affect the operation of the CVC, making it difficult or impossible to pass therapeutic compounds or other materials through the CVC and into the patient's vasculature.


The blockages described above, whether formed inside or outside the CVC, often become coated with a protein substance that provides a shield for bacteria. This protein “shield” makes it difficult to treat bacterial growth within the blockage using antibiotics. Therefore, because of the bacteria-resistant shield, bacterial growth within the blockage can proliferate, increase the size of the blockage, and cause infection. This process is a significant contributing factor to upper extremity deep vein thrombosis (“DVT”).


An obstruction within a CVC can be cleaned while in the patient by using a brush and a small amount of a therapeutic compound, such as a lytic solution. However, it is difficult or impossible to clean the outer surface of a CVC using a brush. In an exemplary embodiment, ultrasonic energy is used to clean one or more portions of a CVC, such as the central lumen 110, the elongate body outer surface 120, or both. Preferably, the ultrasonic energy is used in combination with a blockage removal compound to clean the one or more portions of the CVC. In such embodiments, the ultrasonic energy is preferably configured to enhance the therapeutic effects and/or delivery of the blockage removal compound. For example, the ultrasonic energy can be used to penetrate the protein shield that often covers an occlusion, thereby allowing a blockage removal compound, such as a solution containing an antibacterial agent and/or a thrombus removing compound (e.g., Heparin, Uronkinase, Streptokinase, TPA and other thrombolytics or anti-thrombus agents) to be delivered directly to the occlusion. The ultrasonic energy can be delivered independent of, or simultaneously with, the blockage removal compound. In another use of the system disclosed herein, a CVC is exposed to ultrasonic energy periodically to reduce or prevent accumulation of protein thereon. Preferably, in these embodiments, the ultrasound and/or the blockage removal compound applied while the central venous catheter is positioned in a patient.


One system for using ultrasonic energy to clean a CVC is illustrated in FIG. 3. FIG. 3 is a cross-sectional illustration of the elongate body 100 of a CVC that has been positioned within a patient's vasculature 150. As illustrated, this system can be used to clean deposited material from within the CVC outer surface 120 (such as a fibrin sleeve 130), or from the CVC inner lumen 110 (such as a thrombus or clot 140), or both. Similarly, this system can be used to clean deposited material from the distal end of the CVC, or from an intermediate position on the CVC.


Still referring to FIG. 3, to expose the deposited material to ultrasonic energy, an ultrasound assembly 160 is inserted into, and passed through the elongate body 100. The ultrasound assembly 160, a side view of which is illustrated in FIG. 4, comprises an ultrasound radiating member 165 positioned at the distal end of an elongate support member 167. In an exemplary embodiment, the ultrasound radiating member comprises lead zirconate titanate (“PZT”), although other materials capable of generating mechanical vibrations when exposed to electronic signals can also be used. Although the ultrasound assembly 160 illustrated in FIG. 4 comprises one ultrasound radiating member 165, in a modified embodiment, multiple ultrasound radiating members are positioned along the elongate support member 167. The multiple ultrasound radiating members can be controlled independently of each other. In another modified embodiment, the ultrasound radiating member is mechanically connected to an ultrasound oscillator positioned at the proximal end of the CVC, outside the patient's body; additional information regarding this configuration is provided U.S. Pat. No. 6,524,251, issued on 25 Feb. 2003, and entitled “Ultrasonic Device for Tissue Ablation and Sheath for Use Therewith.”


Additional information regarding controlling a plurality of ultrasound radiating members are provided in U.S. patent application Publication US 2004/0024347 A1, published on 5 Feb. 2004 and entitled “Catheter with Multiple Ultrasound Radiating Members,” the entire disclosure of which is hereby incorporated herein by reference herein. Additional information regarding mounting one or more ultrasound radiating members on an elongate support structure are provided in U.S. patent application Ser. No. 10/751,843, filed on 5 Jan. 2004 and entitled “Ultrasonic Catheter with Axial Energy Field,” the entire disclosure of which is hereby incorporated by reference herein.


A temperature sensor 169 is optionally positioned in a distal region of the elongate support member 169. In other embodiments, the temperature sensor 169 is positioned directly on the ultrasound radiating member 165. In such embodiments, the ultrasound radiating member 165, and optionally the temperature sensor 169, are electrically connected to control circuitry at a proximal end of the ultrasound assembly 160. The temperature sensor can be used to monitor and control the progression of the cleaning procedure. In particular, when removing a blockage from within or around a CVC, a decrease in the temperature at the treatment site can indicate that the blockage has been at least partially removed or dissolved, and that flow has been at least partially reestablished at the treatment site. In addition, the temperature sensor may be used to determine that the radiating member is positioned 165 within the blockage. Additional information regarding using temperature measurements to monitor the progression of an ultrasound-enhanced treatment are provided in U.S. patent application Publication 2003/0220568 A1, published on 27 Nov. 2003 and entitled “Blood Flow Reestablishment Determination,” as well as in U.S. Provisional Patent Applications 60/540,900 (filed 29 Jan. 2004) and 60/540,703 (filed 30 Jan. 2004); the entire disclosure of these three applications is hereby incorporated by reference herein.


As described above, the ultrasound assembly 160 is passed through the CVC to a point that the ultrasound radiating member 165 is positioned adjacent to a blockage. The blockage is located either within the CVC elongate body 100, or outside the CVC elongate body 100. When the ultrasound radiating member 165 is activated via the control circuitry, ultrasonic vibrations are generated, thereby exposing the blockage to ultrasonic energy 170. The blockage can also optionally be exposed to a blockage removal compound to assist in breaking down or dissolving the blockage, such as a thrombolytic solution or an antibacterial solution. The blockage removal compound can be delivered through the CVC itself, or can be independently supplied to the treatment site by, for example, a secondary delivery catheter or a delivery lumen formed integrally with the central venous catheter. In an exemplary embodiment, the ultrasonic energy enhances the effect of the blockage removal compound, as described previously.


In a modified embodiment, the CVC is configured to facilitate the delivery of ultrasonic energy to blockages that form on or within the elongate body. For example, in one embodiment, the elongate body, or optionally only a distal region of the elongate body, is formed from a material that is substantially transparent to ultrasonic energy. This configuration advantageously allows ultrasonic energy generated by an ultrasound radiating member positioned within the central lumen 110 to pass through the elongate body 100 and be absorbed by a blockage outside the CVC.


The ultrasound radiating member 165 need not be positioned within the CVC central lumen 110. For example, the ultrasound assembly can be passed along the outer surface 120 of the CVC in a region 180 (see FIG. 3) between the patient's vasculature 150 and the CVC. In another embodiment, the ultrasound radiating member 150 is embedded within the walls of the CVC, as illustrated in FIGS. 5A and 5B.


As shown in FIGS. 5A and 5B, a modified ultrasound catheter 1100, such as a CVC, generally comprises a multi-component tubular body 1102 having a proximal region (not shown) and a distal region 1106. Suitable materials and dimensions for the ultrasound catheter 1100 can be selected based on the natural and anatomical dimensions of the treatment site and of the percutaneous access site.


The elongate, flexible tubular body 1102 comprises an outer sheath 1130 that is positioned upon an inner core 1110. In an exemplary embodiment, the outer sheath 1130 comprises extruded PEBAX, PTFE, PEEK, PE, polymides, braided polymides and/or other similar materials that are substantially transparent to ultrasonic energy. In an exemplary embodiment, the inner core 1110 comprises polymide or a similar material which, in some embodiments, can be braided to increase the flexibility of the tubular body 1102. The inner core 1110 at least partially defines a delivery lumen 1112 that extends longitudinally along the catheter 1100. The delivery lumen 1112 includes a distal exit port 1114. At a proximal end of the catheter 1100, the delivery lumen 1112 optionally includes a Luer fitting to facilitate the passage of a fluid therethrough.


Still referring to the exemplary embodiment illustrated in FIGS. 5A and 5B, the tubular body distal region 1106 includes the ultrasound radiating member 1124. In a modified embodiment, the ultrasonic energy can be generated by an ultrasound radiating member that is remote from the treatment site; in such embodiments the ultrasonic energy can be transmitted via, for example, a wire to the treatment site, as described above.


As illustrated in FIGS. 5A and 5B, the ultrasound radiating member 1124 is configured as a hollow cylinder. As such, the inner core 1110 extends through the ultrasound radiating member 1124. The ultrasound radiating member 1124 is secured to the inner core 1110 in a suitable manner, such as with an adhesive. A potting material is optionally used to further secure the mounting of the ultrasound radiating member 1124 along the inner core 1110.


In other embodiments, the ultrasound radiating member 1124 is configured with a different shape. For example, the ultrasound radiating member can be configured as a solid rod, a disk, a solid rectangle, a curved element (such as a split cylinder or a curved rectangular element), or a thin block. In such embodiments the ultrasound radiating members are configured with dimensions that allow them to be embedded within the walls of the CVC, as the ultrasound radiating member 1124 illustrated in FIGS. 5A and 5B is embedded in the CVC wall. In other embodiments, wherein the CVC includes a plurality of lumens formed within the catheter, the ultrasound radiating members can be embedded in the catheter walls between the lumens. Because relatively soft materials are often used to form the CVC body, as described above, the catheter walls can be configured with a relatively large thickness, thereby providing ample space to support one or more embedded ultrasound radiating members. Particular characteristics of the ultrasound radiating member can be optimized with routine experimentation based on the particular physical configuration of the CVC body, including the CVC body materials, dimensions, and shape.


Still further, the ultrasound radiating member can comprise a plurality of smaller ultrasound radiating members. However, the illustrated arrangement advantageously provides for enhanced cooling of the ultrasound radiating member 1124. For example, in embodiments wherein a therapeutic compound is delivered through the delivery lumen 1112, the therapeutic compound advantageously serves as a heat sink for removing heat generated by the ultrasound radiating member 1124. In another embodiment, a return path can be formed in the region 1138 between the outer sheath 1130 and the inner core 1110, such that coolant from a coolant system can be directed through the region 1138.


In a modified embodiment, the CVC is configured to caused the ultrasonic energy generated by the ultrasound radiating member to radiate outward from the CVC or inward toward the central lumen. This can be accomplished, for example, by positioning a chamber of high ultrasonic impedance material on the opposite side of the ultrasound radiating member from where the ultrasonic energy is to be directed. This modification can be made with a variety of different ultrasound radiating member configurations, including hollow cylindrical configurations and rectangular configurations. Additional information regarding the use of a backing to direct ultrasonic energy is provided is U.S. Pat. No. 6,676,626, issued on 13 Jan. 2004, and entitled “Ultrasound Assembly with Increased Efficacy,” and in U.S. Pat. No. 6,582,392, issued on 24 Jun. 2003, and entitled “Ultrasound Assembly for Use with a Catheter”, which are hereby incorporated by reference herein in their entirety.


In an exemplary embodiment, the ultrasound radiating member 1124 is selected to produce ultrasonic energy in a frequency range that is well suited for removal of deposited material from the catheter 1100. Suitable frequencies of ultrasonic energy include, but are not limited to, from about 20 kHz to about 20 MHz. In one embodiment, the frequency is between about 500 kHz and 20 MHz, and in another embodiment the frequency is between about 1 MHz and about 3 MHz. In yet another embodiment, the ultrasonic energy has a frequency of about 3 MHz.


As described above, ultrasonic energy is generated from electrical power supplied to the ultrasound radiating member 1124. The electrical power can be supplied through a pair wires 1126, 1128 that extend through the tubular body 1102. In an exemplary embodiment, the electrical wires 1126, 1128 are secured to the inner core 1110, lay along the inner core 1110, and/or extend freely in the region 1138 between the inner core 1110 and the outer sheath 1130. In the illustrated arrangement, the first wire 1126 is connected to the hollow center of the ultrasound radiating member 1124, while the second wire 1128 is connected to the outer periphery of the ultrasound radiating member 1124.


With continued reference to the exemplary embodiment illustrated in FIG. 5B, the catheter 1100 includes at least one temperature sensor 1136 along the tubular body distal region 1106. The temperature sensor 1136 is located on or near the ultrasound radiating element 1124. Suitable temperature sensors include but are not limited to, diodes, thermistors, thermocouples, resistance temperature detectors (“RTDs”), and fiber optic temperature sensors that used thermalchromic liquid crystals. In such embodiments, the temperature sensor is operatively connected to control circuitry through a control wire that extends through the tubular body 1102.


In other embodiments, a vibrational element is embedded in the wall of a CVC. In such embodiments, the vibrational element comprises a metallic compound that can be vibrated by application of an oscillating electromagnetic field from outside the body. For example, an externally-applied electromagnetic field can be used to vibrate a ferro-metallic ring or cylinder embedded in the wall of the catheter 1100. In such embodiments, wires and electrodes used to supply power to an ultrasound radiating member can be eliminated. In certain embodiments, the vibrational element embedded is configured to vibrate upon application of an externally-applied oscillating electric field, or magnetic field, or upon application of externally-applied ultrasonic energy.


Scope of the Invention

For purposes of describing the invention and the advantages achieved over the prior art, certain features, objects and advantages of the invention have been set forth herein. Not necessarily all such features, objects or advantages may be used or achieved in accordance with a particular embodiment of the invention. Thus, for example, the invention may be embodied or carried out in a manner that achieves or optimizes one advantage or group of advantages as taught herein without necessarily achieving other objects or advantages as may be taught or suggested herein. In addition, various methods and procedures have been described above. It should be understood that those methods and procedures should not be limited to the sequence described but may be performed in different orders and that not necessarily all of the steps of a method or procedure needs to be performed. Furthermore, the present invention is not limited to any particular disclosed embodiment, but is limited only by the claims set forth below.

Claims
  • 1. A method for removing a blockage from a central venous catheter comprising: inserting an ultrasound assembly into a central venous catheter positioned in a patient, the ultrasound assembly comprising an ultrasound radiating member mounted on an elongate support structure;positioning the ultrasound assembly within the central venous catheter positioned in a patient such that the ultrasound radiating member is adjacent to a deposited material formed on a portion of the central venous catheter;supplying an electrical current to the ultrasound radiating member to expose the deposited material to ultrasonic energy while the central venous catheter is positioned in a patient; andpassing a blockage removal compound through the central venous catheter to expose the deposited material to the blockage removal compound simultaneously with ultrasonic energy.
  • 2. The method of claim 1, wherein the ultrasound assembly comprises a plurality of ultrasound radiating members.
  • 3. The method of claim 1, wherein the ultrasound assembly comprises a plurality of ultrasound radiating members, and wherein the plurality of ultrasound radiating members are individually controllable.
  • 4. The method of claim 1, further comprising measuring a temperature in a region adjacent to the ultrasound radiating member.
  • 5. The method of claim 1, further comprising: measuring a temperature in a region adjacent to the ultrasound radiating member; andadjusting the electrical current supplied to the ultrasound radiating member based on the measured temperature.
  • 6. The method of claim 1, wherein the blockage removal compound is also passed through the central venous catheter before ultrasonic energy is supplied to the deposited material.
  • 7. A method comprising exposing a deposited material formed on a central venous catheter to ultrasonic energy while the central venous catheter is positioned in a patient and exposing the deposited material formed on the central venous catheter to a blockage removal compound while the central venous catheter is positioned in a patient.
  • 8. The method of claim 7, wherein the blockage removal compound comprises an antibacterial solution.
  • 9. The method of claim 7, wherein the ultrasonic energy has a frequency between about 20 kHz and about 20 MHz.
  • 10. The method of claim 7, the blockage removal compound comprises a thrombus removing agent.
  • 11. The method of claim 7, wherein the blockage removal compound is also delivered to the deposited material before ultrasonic energy is supplied to the deposited material.
  • 12. The method of claim 7, wherein the ultrasonic energy is also delivered to the deposited material after termination of the delivery of blockage removal compound to the deposited material.
  • 13. The method of claim 7, wherein the ultrasonic energy is delivered from an ultrasound assembly positioned within a central lumen of the central venous catheter.
  • 14. The method of claim 7, wherein the ultrasonic energy is delivered from an ultrasound assembly positioned within a central lumen of the central venous catheter, and wherein the ultrasound assembly comprises an ultrasound radiating member mounted on an elongate support structure.
  • 15. The method of claim 7, wherein the ultrasonic energy is delivered from an ultrasound assembly positioned within a central lumen of the central venous catheter, and wherein the ultrasound assembly comprises a plurality of ultrasound radiating members mounted on an elongate support structure.
  • 16. The method of claim 7, further comprising measuring a temperature adjacent to the deposited material.
  • 17. The method of claim 7, further comprising: measuring a temperature adjacent to the deposited material; andadjusting the amount of ultrasonic energy delivered to the deposited material based on the measured temperature.
  • 18. The method of claim 7, wherein the ultrasonic energy is delivered from an ultrasound radiating member embedded in an elongate body of the central venous catheter.
  • 19. The method of claim 7, wherein the blockage removal compound is delivered to the deposited material through the central venous catheter.
  • 20. The method of claim 7, wherein the blockage removal compound is delivered to the deposited material through a delivery lumen formed integrally with the central venous catheter.
PRIORITY CLAIM

This application is a continuation of U.S. patent application Ser. No. 10/828,938 (filed 21 Apr. 2004), which claims the benefit of U.S. Provisional Application 60/464,673 (filed 22 Apr. 2003), the entire disclosure of which is hereby incorporated in its entirety by reference herein.

US Referenced Citations (181)
Number Name Date Kind
3433226 Boyd Mar 1969 A
4040414 Suroff Aug 1977 A
4176662 Frazer Dec 1979 A
4319580 Colley Mar 1982 A
4531943 Van Tassel Jul 1985 A
4549533 Cain et al. Oct 1985 A
4698058 Greenfeld et al. Oct 1987 A
4739768 Engelson Apr 1988 A
4750902 Wuchinich Jun 1988 A
4808153 Parisi Feb 1989 A
4841977 Griffith et al. Jun 1989 A
4870953 Donmicheal Oct 1989 A
4906238 Greenfeld et al. Mar 1990 A
4920954 Alliger May 1990 A
4924863 Sterzer May 1990 A
4936281 Stasz Jun 1990 A
4948587 Kost et al. Aug 1990 A
5021044 Sharkawy Jun 1991 A
5059851 Corl et al. Oct 1991 A
5108369 Ganguly et al. Apr 1992 A
5158071 Umemura et al. Oct 1992 A
5163421 Bernstein et al. Nov 1992 A
5197946 Tachibana Mar 1993 A
5226421 Frisbie et al. Jul 1993 A
5250034 Appling Oct 1993 A
5267954 Nita Dec 1993 A
5267985 Shimada Dec 1993 A
5269291 Carter Dec 1993 A
5269297 Weng et al. Dec 1993 A
5271406 Ganguly et al. Dec 1993 A
5282785 Shapland et al. Feb 1994 A
5286254 Shapland Feb 1994 A
5295484 Marcus Mar 1994 A
5304115 Pflueger et al. Apr 1994 A
5312328 Nita et al. May 1994 A
5318014 Carter Jun 1994 A
5327891 Rammler Jul 1994 A
5328470 Nabel Jul 1994 A
5342292 Nita et al. Aug 1994 A
5344435 Turner Sep 1994 A
5345940 Seward et al. Sep 1994 A
5353798 Sieben Oct 1994 A
5354279 Hofling Oct 1994 A
5362309 Carter Nov 1994 A
5368036 Tanaka et al. Nov 1994 A
5368557 Nita et al. Nov 1994 A
5380273 Dubrul et al. Jan 1995 A
5382228 Nita et al. Jan 1995 A
5385148 Lesh et al. Jan 1995 A
5421338 Crowley Jun 1995 A
5423797 Adrian et al. Jun 1995 A
5427118 Nita et al. Jun 1995 A
5429136 Milo et al. Jul 1995 A
5445155 Sieben Aug 1995 A
5447509 Mills et al. Sep 1995 A
5447510 Jensen Sep 1995 A
5454795 Samson Oct 1995 A
5458568 Racchini Oct 1995 A
5462523 Samson Oct 1995 A
5465726 Dickinson Nov 1995 A
5474531 Carter Dec 1995 A
5496267 Drasler et al. Mar 1996 A
5496294 Hergenrother et al. Mar 1996 A
5498238 Shapland Mar 1996 A
5503155 Salmon et al. Apr 1996 A
5514092 Forman May 1996 A
5520189 Malinowski May 1996 A
5531715 Engelson et al. Jul 1996 A
5533986 Mottola et al. Jul 1996 A
5542917 Nita et al. Aug 1996 A
5560362 Sliwa, Jr. et al. Oct 1996 A
5569197 Helmus et al. Oct 1996 A
5571086 Kaplan et al. Nov 1996 A
5588432 Crowley Dec 1996 A
5599326 Carter Feb 1997 A
5603694 Brown et al. Feb 1997 A
5606974 Castellano Mar 1997 A
5609574 Kaplan et al. Mar 1997 A
5620479 Diederich Apr 1997 A
5628728 Tachibana et al. May 1997 A
5628730 Shapland May 1997 A
5630837 Crowley May 1997 A
5713848 Dubrul et al. Feb 1998 A
5725494 Brisken Mar 1998 A
5728062 Brisken Mar 1998 A
5735811 Brisken Apr 1998 A
5782811 Samson et al. Jul 1998 A
5807395 Mulier et al. Sep 1998 A
5827529 Ono et al. Oct 1998 A
5830127 DeCastro Nov 1998 A
5836896 Rosenschein Nov 1998 A
5836946 Diaz et al. Nov 1998 A
5842994 TenHoff et al. Dec 1998 A
5895398 Wensel et al. Apr 1999 A
5916192 Nita et al. Jun 1999 A
5928186 Homsma et al. Jul 1999 A
5931805 Brisken Aug 1999 A
5951494 Wang et al. Sep 1999 A
5971949 Levin et al. Oct 1999 A
5976120 Chow et al. Nov 1999 A
5997497 Nita et al. Dec 1999 A
6001069 Tachibana et al. Dec 1999 A
6024703 Zanelli et al. Feb 2000 A
6024718 Chen et al. Feb 2000 A
6053868 Geistert et al. Apr 2000 A
6096000 Tachibana et al. Aug 2000 A
6110314 Nix et al. Aug 2000 A
6113558 Rosenschein et al. Sep 2000 A
6120454 Suorsa et al. Sep 2000 A
6135971 Hutchinson et al. Oct 2000 A
6143013 Samson et al. Nov 2000 A
6176842 Tachibana et al. Jan 2001 B1
6182666 Dobak, III Feb 2001 B1
6206831 Suorsa et al. Mar 2001 B1
6210356 Anderson et al. Apr 2001 B1
6228046 Brisken May 2001 B1
6234958 Snoke et al. May 2001 B1
6235024 Tu May 2001 B1
6241703 Levin et al. Jun 2001 B1
6287271 Dubrul et al. Sep 2001 B1
6296619 Brisken et al. Oct 2001 B1
6361500 Masters Mar 2002 B1
6361531 Hissong Mar 2002 B1
6368315 Gillis et al. Apr 2002 B1
6372498 Newman et al. Apr 2002 B2
6379320 Lafon et al. Apr 2002 B1
6387035 Jung, Jr. et al. May 2002 B1
6423026 Gesswein et al. Jul 2002 B1
6433464 Jones Aug 2002 B2
6437487 Mohr, III et al. Aug 2002 B1
6461314 Pant et al. Oct 2002 B1
6508775 McKenzie et al. Jan 2003 B2
6524251 Rabiner et al. Feb 2003 B2
6524300 Meglin Feb 2003 B2
6542767 McNichols et al. Apr 2003 B1
6542797 Lohmiller Apr 2003 B2
6551337 Rabiner et al. Apr 2003 B1
6554801 Steward et al. Apr 2003 B1
6562021 Derbin et al. May 2003 B1
6582392 Bennett et al. Jun 2003 B1
6589182 Loftman et al. Jul 2003 B1
6599288 Maguire et al. Jul 2003 B2
6607502 Maguire et al. Aug 2003 B1
6647755 Rabiner et al. Nov 2003 B2
6652547 Rabiner et al. Nov 2003 B2
6660013 Rabiner et al. Dec 2003 B2
6663613 Evans et al. Dec 2003 B1
6676626 Bennett et al. Jan 2004 B1
6692494 Cooper et al. Feb 2004 B1
6711953 Hayashi et al. Mar 2004 B2
6723063 Zhang et al. Apr 2004 B1
6740040 Mandrusov et al. May 2004 B1
6824515 Suorsa et al. Nov 2004 B2
6855123 Nita Feb 2005 B2
6979293 Hansmann et al. Dec 2005 B2
7089063 Lesh et al. Aug 2006 B2
20010037106 Shadduck Nov 2001 A1
20020000763 Jones Jan 2002 A1
20020022833 Maguire et al. Feb 2002 A1
20020032394 Brisken et al. Mar 2002 A1
20020133111 Shadduck Sep 2002 A1
20020151825 Rubenchik et al. Oct 2002 A1
20020161325 Hansmann Oct 2002 A1
20030023261 Tomaschko et al. Jan 2003 A1
20030028173 Forsberg Feb 2003 A1
20030036705 Hare et al. Feb 2003 A1
20030040698 Makin et al. Feb 2003 A1
20030069590 Rabiner et al. Apr 2003 A1
20030109812 Corl et al. Jun 2003 A1
20030236539 Rabiner et al. Dec 2003 A1
20040015061 Currier et al. Jan 2004 A1
20040015084 Flesch et al. Jan 2004 A1
20040015138 Currier et al. Jan 2004 A1
20040019318 Wilson et al. Jan 2004 A1
20040024347 Wilson et al. Feb 2004 A1
20040024393 Nita et al. Feb 2004 A1
20040039311 Nita et al. Feb 2004 A1
20040049148 Rodriguez et al. Mar 2004 A1
20040068189 Wilson et al. Apr 2004 A1
20040199228 Wilson Oct 2004 A1
20050215942 Abrahamson et al. Sep 2005 A1
Foreign Referenced Citations (24)
Number Date Country
40 05 743 Aug 1991 DE
0 629 382 Dec 1994 EP
1 103 281 May 2001 EP
H02-180275 Jul 1990 JP
WO 8904142 May 1989 WO
WO 9211815 Jul 1992 WO
WO 9316646 Sep 1993 WO
WO 9501751 Jan 1995 WO
WO 9509571 Apr 1995 WO
WO 9526777 Oct 1995 WO
WO 9629935 Oct 1996 WO
WO 9719644 Jun 1997 WO
WO 9719645 Jun 1997 WO
WO 9848711 Nov 1998 WO
WO 9856462 Dec 1998 WO
WO 9916360 Apr 1999 WO
WO 0000095 Jan 2000 WO
WO 0038580 Jul 2000 WO
WO 0113357 Feb 2001 WO
WO 0154754 Aug 2001 WO
WO 03030751 Apr 2003 WO
WO 03051208 Jun 2003 WO
WO 2004007012 Jan 2004 WO
WO 2004012609 Feb 2004 WO
Related Publications (1)
Number Date Country
20050197619 A1 Sep 2005 US
Provisional Applications (1)
Number Date Country
60464673 Apr 2003 US
Continuations (1)
Number Date Country
Parent 10828938 Apr 2004 US
Child 11046052 US